Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: The study of β-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell

Pancreas

Volumn 38, Issue 1, 2009, Pages 94-100

  Zhang, Dong ^a   Ma, Qingyong ^a   Shen, Sugang ^a   Hu, Hengtong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Pancreatic cancer cell; Propranolol

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ACTIN; BETA ADRENERGIC RECEPTOR; BUTOXAMINE; CASPASE 3; CASPASE 8; CASPASE 9; FLUORESCEIN ISOTHIOCYANATE; HOE 33342; LIPOCORTIN 5; MESSENGER RNA; METOPROLOL; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROPIDIUM IODIDE; PROPRANOLOL; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; NICK END LABELING; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADRENERGIC BETA-ANTAGONISTS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTOXAMINE; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METOPROLOL; PANCREATIC NEOPLASMS; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RNA, MESSENGER;

EID: 59649084222     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318184f50c     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol. 2004;34:238-244.
3. Guo XZ, Cui ZM. Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 2005;31:13-22.
4. Kloppel GA. Pathology of nonneuroendocrine pancreatic tumors. In: Go VLW, Dimagno EP, Gardner JD, et al, eds. The Pancreas: Biology, Pathobiology, and Disease. New York, PA: Raven Press; 1993:871-879.
5. Lutz H, Brian KK. Adrenergic receptors from molecular structure to in vivo function. Trends Cardiovasc Med. 1997;7:137-145.
6. 2- adrenergic receptor function and regulation. Proc Am Thorac Soc. 2005;2: 292-296.
7. Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer. 2002;2:455-463.
8. Weddle DL, Tithoff P, Williams M, et al. A-Adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis. 2001;22:473-479.
9. Schuller HM, Porter B, Riechert A. A-Adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol. 2000;126:624-630.
10. Burris JF. A-Blocks, dyslipidemia, and coronary heart disease. Arch Intern Med. 1993;153:2085-2092.
11. Bondjers G. Anti-atherosclerotic effects of β-blocks. Eur Heart J. 1994;15(suppl C):8-15.
12. Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action. Cancer Res. 2002;62: 597-602.
13. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by >1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000;60:4550-4555.
14. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol. 1997;80:15-19.
15. Hsieh M, Conti M. G-protein-coupled receptor signaling and the EGF network in endocrine systems. Trends Endocrinol Metab. 2005;16: 320-326.
16. 2 adrenergic receptor-Src protein kinase complexes. Science. 1999;283:655-661.
17. 3K team to hold inflammation and cancer at bay. Pharmacol Therapeut. 2008;118: 192-205.
18. James AM, Linda SS, William HC, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263-1284.
19. Askari MD, Tsao MS, Schuller HM. The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. J Cancer Res Clin Oncol. 2005;131:639-648.
20. Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol. 2004;54:S69-S77.
21. Murphy LO, Cluck MW, Lovas S, et al. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br J Cancer. 2001;84:926-935.
22. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003;9: 346-354.
23. Mimeault M, Brand RE, Sasson AA, et al. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas. 2005;31:301-316.
24. Boyle P, Maisonneuve P, Bueno MB, et al. Cigarette smoking and pancreas cancer: a case-control study of the search programme of the IARC. Int J Cancer. 1996;67:63-71.
25. Kuller LH. Dietary fat and chronic diseases: epidemiologic overview. J Am Diet Assoc. 1997;97:S9-S15.
26. Fitzpatrick AL, Daling JR, Furberg CD, et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11:534-542.